Hong Kong–listed biopharmaceutical company Antengene-B reported the repurchase of 89,500 ordinary shares on 29 September 2026 under its existing buyback mandate approved on 10 June 2026. The transaction, disclosed in a Next Day Disclosure Return filed with the Stock Exchange of Hong Kong, was executed on-market at prices ranging between HKD 3.365 and HKD 3.47 per share, for an aggregate consideration of approximately HKD 0.30 million. The volume-weighted average purchase price was HKD 3.3994 per share.

Following the buyback, Antengene-B’s issued share capital (excluding treasury shares) declined by 0.013 % to 687.03 million shares, while treasury shares increased to 2.51 million. The company’s total issued share count remained unchanged at 689.54 million, as none of the repurchased shares have been cancelled; all are being held in treasury.

Cumulatively, Antengene-B has repurchased 2.30 million shares since receiving approval for the current mandate, representing 0.34 % of the company’s issued shares outstanding as at the mandate date. The issuer remains subject to a moratorium on issuing new shares or disposing of treasury shares until 29 October 2026, in accordance with Hong Kong Listing Rules.

The company confirmed that all repurchase activities complied with the Main Board Listing Rules and that no material changes have been made to the explanatory statement filed with the exchange in April 2026.